Ortho-Clinical Diagnostics, Inc.

Ortho-Clinical Diagnostics, Inc., a HUBZone joint venture manufacturer of diagnostic laboratory equipment and consumables, operates as a prime contractor supplying blood bank analyzers, clinical chemistry systems, immunodiagnostic reagents, and associated services to federal healthcare agencies. The company is a wholly owned subsidiary of Quidelortho Corporation, headquartered in Raritan, New Jersey, and competes in full-and-open procurements without reliance on SBA set-asides.

Ortho-Clinical Diagnostics' federal footprint centers on medical diagnostic goods and services delivered through a mix of delivery orders, blanket purchase agreements, and indefinite delivery contracts. Representative work includes a $1.33 million firm fixed-price delivery order from Veterans Integrated Service Network 22 (August 2026) for a dry chemistry/immunochemistry system placed in Albuquerque, New Mexico under the Critical Analyzers, Laboratory (FSS-66-III) GSA Schedule; a $310.3 million BPA call from VISN 23 for chemistry immunochemistry supplies (October 2025); a $141.3 million delivery order from Indian Health Service for preventative maintenance on a Vitros XT 3400 chemistry analyzer at Pinon Health Center through August 2028; and a $360 thousand delivery order from Indian Health Service (September 2025) for VITROS 5600 laboratory reagents and supplies running through August 2030. The company also supplies the Defense Health Agency's medical supply chain with high-volume, low-value orders of specialized blood bank reagents, test slides, and analyzer consumables at unit prices typically below $5,000.

Customer concentration shows dual peaks across volume and dollar value. By award count, the Defense Logistics Agency Troop Support Medical dominates at 2,641 awards ($65 million combined potential value), followed by the Indian Health Service (621 awards, $59.5 million) and the Bureau of Medicine and Surgery (198 awards, $47.7 million). By combined potential value, the Veterans Integrated Service Network 9 leads at $116.2 million across 142 awards, followed by VISN 22 at $88.5 million (107 awards) — a split driven by large multi-million-dollar equipment and maintenance contracts housed within the VA's regional networks. Together, these top five customer agencies account for 71% of recent awards.

The Critical Analyzers, Laboratory (FSS-66-III) GSA Schedule is the dominant vehicle, holding 2,875 task orders with $607.1 million in combined potential value. The company also maintains a portfolio of single-award and multiple-award IDCs, including a $1.64 million indefinite delivery contract with VA VISN 12 (running through February 2030) for Ortho Vision Analyzer reagents and services, a $2.1 million BPA with the Air Force (April 2026 through April 2031) for blood bank testing supplies and services, and an $80 thousand single-award BPA with Indian Health Service's Phoenix Area Office (May 2025 through May 2030) for blood bank supplies to Hopi Health Care Center. Two additional IDCs — SPE2D018D0005 and SPE2DE21D0007 — carry 1,431 and 1,206 task orders respectively with combined potential values of $1.8 million and $4 million.

Activity has ranged from 508 awards in 2022 to 644 in 2024, with a drop to 429 in 2025 and only 25 awards recorded so far in 2026 (source date July 15, 2026). Fifty-two awards carrying combined potential value of $18.7 million reach ultimate completion within the next twenty-four months, presenting modest recompete exposure. The vendor operates exclusively as a prime contractor; the source records zero sub-award activity.

SCI-reported invoicing from federal service contracts above the $150,000 threshold totaled only $4 thousand across FY2022–FY2024, spanning 0.4 FTEs in FY2024. This minimal SCI footprint reflects the company's business model: the vast majority of federal revenue flows through goods procurement (analyzers, reagents, consumables) and maintenance services that fall outside SCI's product-reporting scope and sub-$150,000 transaction thresholds. The company operates its own delivery teams with zero sub-engagement on SCI-reportable contracts.

Ortho-Clinical Diagnostics' federal portfolio is concentrated in three NAICS categories: Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers (2,641 awards), In-Vitro Diagnostic Substance Manufacturing (1,959 awards), and Analytical Laboratory Instrument Manufacturing (1,072 awards), with PSC codes split between Laboratory Equipment and Supplies, In-Vitro Diagnostic Substances, and Drugs and Biologicals. The company maintains a long award history dating to 1979 and has served 67 distinct federal agencies; core customer relationships span the Department of Veterans Affairs (multiple VISNs), Defense Logistics Agency, Indian Health Service, Department of Defense medical treatment facilities, and the National Institutes of Health. Combined potential value across all 5,999 awards stands at $805.4 million, with $431.1 million obligated (54% of potential value). The company's federal contracting posture is characterized by high-volume, low-dollar routine consumables and maintenance orders anchored to GSA Schedule vehicles and VA-wide IDCs, supplemented by occasional large-dollar equipment and multi-year maintenance contracts.